Gongyan Chen

A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study

Huaqiang Zhou, Qing Zhou, Qisen Guo, Wei Guo et autres

cn, us, fr, de, gb (code pays fourni par la source)

Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum in Chinese Participants With Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer: Phase 3 LEAP-006 China Extension Study

Caicun Zhou, Yanqiu Zhao, Yun Fan, Jie Hu et autres

Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

Yuankai Shi, Lin Wu, Yinghua Ji, Gongyan Chen et autres

cn (code pays fourni par la source)

Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial

Tingting Liu, Junyi He, Yalan Wang, Yuwen Yang et autres

cn (code pays fourni par la source)

Supplementary Data 1 from HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer

Tao Jiang, Qiqi Jin, Jiahao Wang, Fengying Wu et autres

Data from HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer

Tao Jiang, Qiqi Jin, Jiahao Wang, Fengying Wu et autres

Supplementary Data 1 from HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer

Tao Jiang, Qiqi Jin, Jiahao Wang, Fengying Wu et autres

Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial

Baohui Han, Trevor Feinstein, Yuankai Shi, Gongyan Chen et autres

cn, us, au (code pays fourni par la source)

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

Shun Lü, Yiping Zhang, Guojun Zhang, Jianying Zhou et autres

cn, hk (code pays fourni par la source)

Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study

Jin‐Ji Yang, Jianying Zhou, Si‐Yang Maggie Liu, Mingjun Li et autres

cn, hk (code pays fourni par la source)

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)

Shun Lü, Xiaorong Dong, Hong Jian, Jianhua Chen et autres

cn, hk, us (code pays fourni par la source)

IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer

Yi‐Long Wu, Shun Lü, Gongyan Chen, Jianxing He et autres

cn (code pays fourni par la source)